UBS Raises Repligen's Price Target to $200, Citing 20% Order Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2026
0mins
Source: Yahoo Finance
- Price Target Increase: UBS raised Repligen's price target from $190 to $200 while maintaining a Buy rating, reflecting confidence in the company's leadership in the bioprocessing sector recovery.
- Strong Order Growth: Repligen reported over 20% order growth and is expanding its footprint in Edge manufacturing, positioning itself as a core beneficiary as biopharma companies reshore production closer to primary markets by 2026.
- New Product Launch: On December 16, Repligen launched three new high-performance chromatography resins designed to meet next-gen bioprocessing needs, particularly for viral vectors in gene therapy, thereby enhancing its protein portfolio.
- Technological Innovation: The new resins utilize Tantti DuloCore base bead technology to improve molecule stability, accelerate product development, and enhance overall process economics for gene therapy developers, thereby increasing processing efficiency for complex biotherapeutic workflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGEN
Wall Street analysts forecast RGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGEN is 189.00 USD with a low forecast of 165.00 USD and a high forecast of 207.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 156.370
Low
165.00
Averages
189.00
High
207.00
Current: 156.370
Low
165.00
Averages
189.00
High
207.00
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UBS Raises Repligen's Price Target to $200, Citing 20% Order Growth
- Price Target Increase: UBS raised Repligen's price target from $190 to $200 while maintaining a Buy rating, reflecting confidence in the company's leadership in the bioprocessing sector recovery.
- Strong Order Growth: Repligen reported over 20% order growth and is expanding its footprint in Edge manufacturing, positioning itself as a core beneficiary as biopharma companies reshore production closer to primary markets by 2026.
- New Product Launch: On December 16, Repligen launched three new high-performance chromatography resins designed to meet next-gen bioprocessing needs, particularly for viral vectors in gene therapy, thereby enhancing its protein portfolio.
- Technological Innovation: The new resins utilize Tantti DuloCore base bead technology to improve molecule stability, accelerate product development, and enhance overall process economics for gene therapy developers, thereby increasing processing efficiency for complex biotherapeutic workflows.
Continue Reading
Repligen Elects Martin Madaus as Board Chair Effective March 13
- Board Transition: Repligen announced the election of Martin Madaus as chair of the board effective March 13, following the retirement of Tony Hunt, indicating a strategic leadership shift within the company.
- Experienced Leadership: Having served as a director since February 2023, Madaus brings 36 years of industry experience, which not only enhances the company's management perspective but also aids in driving future growth initiatives.
- Continuity in Advisory Role: Tony Hunt will remain as an advisor until March 2027, ensuring stability and continuity during the transition period, which helps maintain investor confidence in the company's direction.
- Market Reaction: In pre-market trading on Nasdaq, Repligen's stock rose by 0.33% to $170, reflecting positive market sentiment towards the new chair and potentially fostering future growth for the company.
Continue Reading